These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 30559264)

  • 21. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?
    Ellsworth P; Ma A
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):219-225. PubMed ID: 34889356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].
    Nogami K
    Rinsho Ketsueki; 2019; 60(5):475-479. PubMed ID: 31168016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Emicizumab: a paradigm shift in hemophilia treatment].
    Nogami K
    Rinsho Ketsueki; 2020; 61(5):536-541. PubMed ID: 32507821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
    Díaz-Ricart M; Isola IM; Escolar G
    Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Confronting COVID-19: Issues in Hemophilia and Congenital Bleeding Disorders.
    Coppola A; Tagliaferri A; Rivolta GF; Quintavalle G; Franchini M
    Semin Thromb Hemost; 2020 Oct; 46(7):819-822. PubMed ID: 32512586
    [No Abstract]   [Full Text] [Related]  

  • 27. How do we optimally utilize factor concentrates in persons with hemophilia?
    Lim MY
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):206-214. PubMed ID: 34889393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
    Lenting PJ; Denis CV; Christophe OD
    Blood; 2017 Dec; 130(23):2463-2468. PubMed ID: 29042366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia.
    Tiede A
    Hamostaseologie; 2017; 37(4):307-310. PubMed ID: 29582931
    [No Abstract]   [Full Text] [Related]  

  • 31. Antibodies in the Treatment of Haemophilia A-A Biochemical Perspective.
    Ferrière S; Lenting PJ
    Hamostaseologie; 2019 Feb; 39(1):36-41. PubMed ID: 30695798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
    Le Quellec S
    Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.
    Müller J; Pekrul I; Pötzsch B; Berning B; Oldenburg J; Spannagl M
    Thromb Haemost; 2019 Sep; 119(9):1384-1393. PubMed ID: 31203578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
    Yada K; Nogami K
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The promise and challenges of bioengineered recombinant clotting factors.
    Pipe SW
    J Thromb Haemost; 2005 Aug; 3(8):1692-701. PubMed ID: 16102035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current developments in hemostatic treatment for patients with hemophilia].
    Nogami K
    Rinsho Ketsueki; 2021; 62(8):1213-1221. PubMed ID: 34497209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of recombinant coagulation factors in treating hemophilia.
    Morfini M; Rapisarda CAP
    Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pioneering therapeutic proteins in hemophilia care through innovative technologies.
    Pabinger-Fasching I; Négrier C
    Thromb Res; 2016 May; 141 Suppl 3():S1. PubMed ID: 27288062
    [No Abstract]   [Full Text] [Related]  

  • 40. The More Recent History of Hemophilia Treatment.
    Franchini M; Mannucci PM
    Semin Thromb Hemost; 2022 Nov; 48(8):904-910. PubMed ID: 36108649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.